.png?width=150&name=MMS%20logo_without%20Tagline%20(Full%20Color).png "MMS logo_without Tagline (Full Color)")
Why COVID-19 testing devices require a high level of specificity
by Patrick Hannon, PhD, Japie Lowings, and Aditya Gadiko
GREEN VALLEY PHARMACEUTICAL AND MMS HOLDINGS COLLABORATE TO GAIN FDA APPROVAL TO BEGIN CLINICAL TRIALS FOR THE FIRST ALZHEIMER’S DRUG IN 17 YEARS
CANTON, Mich. and SHANGHAI (May 5, 2020) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – ...
With Safety, Urgency, and Innovation: How an Award-Winning CRO Operates During COVID-19
The COVID-19 pandemic has impacted the way many pharmaceutical, biotech, and CRO companies are working, ...
Whitepaper: Six Changes that Pharmaceutical Companies Should Consider in Response to COVID-19
In the wake of the global pandemic of COVID-19, also known and SARS-COV-2, regulators, health authorities, ...